China is challenging the United States for market share and jobs in one of the highest value-added, most innovation-intensive industries—and the risks extend not just to the U.S. economy, but to global biopharma innovation.
March 21, 2017
Bipartisan collaboration on the Hill has proven scant in the opening weeks of the Trump era, but the opportunity to reauthorize the Prescription Drug User Fee Act provides a welcome occasion for bipartisan comity while extending legislation that has played a foundational role in underpinning U.S. life-sciences leadership and helping bring safe, innovative cures to patients faster, writes Stephen Ezell in Innovation Files.
February 27, 2017
PDUFA enables a safe, timely, and efficient process of drug evaluation while applying best practices in regulatory science that support America’s global leadership in biomedical innovation.
November 3, 2016
How the Trans-Pacific Partnership Agreement Will Strengthen Singapore’s Innovation Economy (Like America’s)
As Singapore continues its efforts to transform a small island nation into a global innovation hub, the innovation-enabling trade regime the Trans-Pacific Partnership fosters will benefit all industries but especially advanced technology ones, in areas such as life sciences and information technology, on which Singapore’s economy (like America’s) increasingly thrives, writes John Wu in Innovation Files.
November 2, 2016
When a Breakthrough Drug Receives an Additional Year of Market Exclusivity, 20% More Drugs are Approved in the Same Class.
Every additional year of market exclusivity given to a breakthrough compound increases the number of subsequent drugs approved in that class by between 18 and 25 percent—20 percent on average, writes John Wu in Innovation Files.
July 14, 2016
The UN high-level access to medicines panel must consider the complete range of factors impacting access to medicines, writes Stephen Ezell in Innovation Files.
July 12, 2016
In Innovation Files, Stephen Ezell provides an overview of localization barriers to trade in the life sciences sector recently enacted by countries around the world.
July 11, 2016
Spurring biopharmaceutical innovation to understand and cure brain diseases and disorders could improve health outcomes for more than 50 million Americans while increasing GDP by up to $1.5 trillion or more.
July 11, 2016
Join ITIF for the release of a new report examining the potential economic gains the United States could reap from biopharma innovation that enables improved diagnosis, treatment, cures, and even prevention of mental and neurological health conditions.
June 28, 2016
Stephen Ezell spoke at a Center Forward Congressional briefing on “Why Life-Sciences Innovation is Politically Purple,” explaining that U.S. leadership in global life-sciences innovation has resulted from a strong bi-partisan commitment to support robust levels of public investment in basic life-sciences research.
April 29, 2016
The unintended exploitation of Bayh-Dole “march-in” rights would significantly harm biomedical innovation, writes Stephen Ezell in Innovation Files.